DOID:1749: Difference between revisions

Latest revision as of 16:49, 12 September 2014

squamous cell carcinoma

Namespace:

FANTOM

Definition:

"A carcinoma that derives_from squamous epithelial cells." [url:http://en.wikipedia.org/wiki/Squamous_cell_carcinoma, url:http://www.medicinenet.com/skin_cancer/page2.htm]

Xrefs:

links:

MSH:D002294
NCI:C2929
SNOMEDCT_2010_1_31:154605007
SNOMEDCT_2010_1_31:189566008
SNOMEDCT_2010_1_31:28899001
SNOMEDCT_2010_1_31:402815007
UMLS_CUI:C0007137

UMLS_CUI:C0751688

Synonyms:

"epidermoid carcinoma" EXACT [CSP2005:2000-3145]
"malignant squamous cell tumor" EXACT [NCI2004_11_17:C4971]
"squamous carcinoma" EXACT [NCI2004_11_17:C2929]
"squamous cell cancer" EXACT []
"squamous cell carcinoma (disorder)" EXACT [SNOMEDCT_2005_07_31:402815007]
"squamous cell carcinoma (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:28899001]
"squamous cell carcinoma NOS (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:189566008]
"squamous cell Epithelioma" EXACT [NCI2004_11_17:C8999]

Alt_id:

DOID:5512

Ontology association Each term has an is_a parent in the Disease Ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to DISEASE ontologies. link to ontology dataset data

Parents

is_a:	DOID:305(carcinoma)

Children

is a:	DOID:4830 (adenosquamous carcinoma)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples

Human (Homo sapiens)

10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
10426-106D3 (epidermoid carcinoma cell line:A431)
10431-106D8 (epidermoid carcinoma cell line:Ca Ski)
10434-106E2 (oral squamous cell carcinoma cell line:Ca9-22)
10457-106G7 (squamous cell lung carcinoma cell line:LC-1F)
10463-106H4 (squamous cell carcinoma cell line:EC-GI-10)
10486-107A9 (squamous cell lung carcinoma cell line:EBC-1)
10501-107C6 (squamous cell lung carcinoma cell line:RERF-LC-AI)
10512-107D8
10532-107G1

... further results Mouse (Mus musculus)

10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
10426-106D3 (epidermoid carcinoma cell line:A431)
10431-106D8 (epidermoid carcinoma cell line:Ca Ski)
10434-106E2 (oral squamous cell carcinoma cell line:Ca9-22)
10457-106G7 (squamous cell lung carcinoma cell line:LC-1F)
10463-106H4 (squamous cell carcinoma cell line:EC-GI-10)
10486-107A9 (squamous cell lung carcinoma cell line:EBC-1)
10501-107C6 (squamous cell lung carcinoma cell line:RERF-LC-AI)
10512-107D8
10532-107G1

... further results

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with DOID:1749 (squamous cell carcinoma), sorted by p-values Analyst: Hideya Kawaji link to source dataset human : data mouse : data

Show entries

Search:

P-value	FFCP	Short description
1.52e-75	FFCP PHASE1:Hg19::chr1:209944599..209944616,-	p@chr1:209944599..209944616, -
1.52e-75	FFCP PHASE2:Hg19::chr1:209944599..209944616,-	p@chr1:209944599..209944616, -
2.65e-72	FFCP PHASE2:Hg19::chr11:70245655..70245668,-	p@chr11:70245655..70245668, -
2.65e-72	FFCP PHASE1:Hg19::chr11:70245655..70245668,-	p@chr11:70245655..70245668, -
2.04e-63	FFCP PHASE1:Hg19::chr1:55436540..55436544,-	p@chr1:55436540..55436544, -
2.04e-63	FFCP PHASE2:Hg19::chr1:55436540..55436544,-	p@chr1:55436540..55436544, -
3.14e-63	FFCP PHASE1:Hg19::chr7:55053327..55053342,+	p@chr7:55053327..55053342, +
3.14e-63	FFCP PHASE2:Hg19::chr7:55053327..55053342,+	p@chr7:55053327..55053342, +
8.34e-63	FFCP PHASE1:Hg19::chr3:151034414..151034434,-	p2@GPR87
8.34e-63	FFCP PHASE2:Hg19::chr3:151034414..151034434,-	p2@GPR87
1.33e-60	FFCP PHASE1:Hg19::chr6:19418214..19418218,-	p@chr6:19418214..19418218, -
1.33e-60	FFCP PHASE2:Hg19::chr6:19418214..19418218,-	p@chr6:19418214..19418218, -
4.0e-57	FFCP PHASE2:Hg19::chr1:209945462..209945477,-	p@chr1:209945462..209945477, -
4.0e-57	FFCP PHASE1:Hg19::chr1:209945462..209945477,-	p@chr1:209945462..209945477, -
4.38e-56	FFCP PHASE1:Hg19::chr7:55053266..55053282,+	p@chr7:55053266..55053282, +
4.38e-56	FFCP PHASE2:Hg19::chr7:55053266..55053282,+	p@chr7:55053266..55053282, +
4.21e-53	FFCP PHASE2:Hg19::chr1:153530641..153530645,-	p@chr1:153530641..153530645, -
4.21e-53	FFCP PHASE1:Hg19::chr1:153530641..153530645,-	p@chr1:153530641..153530645, -
5.73e-53	FFCP PHASE1:Hg19::chr21:38631055..38631068,-	p@chr21:38631055..38631068, -
5.73e-53	FFCP PHASE2:Hg19::chr21:38631055..38631068,-	p@chr21:38631055..38631068, -
1.69e-50	FFCP PHASE1:Hg19::chr8:126044339..126044344,-	p@chr8:126044339..126044344, -
1.69e-50	FFCP PHASE2:Hg19::chr8:126044339..126044344,-	p@chr8:126044339..126044344, -
2.43e-49	FFCP PHASE1:Hg19::chr17:39755734..39755747,-	p@chr17:39755734..39755747, -
2.43e-49	FFCP PHASE2:Hg19::chr17:39755734..39755747,-	p@chr17:39755734..39755747, -
2.53e-46	FFCP PHASE2:Hg19::chr10:54215029..54215039,-	p5@ENST00000435813, p5@uc001jjs.2
2.53e-46	FFCP PHASE1:Hg19::chr10:54215029..54215039,-	p5@ENST00000435813, p5@uc001jjs.2
1.76e-45	FFCP PHASE1:Hg19::chr18:61586483..61586487,+	p@chr18:61586483..61586487, +
1.76e-45	FFCP PHASE2:Hg19::chr18:61586483..61586487,+	p@chr18:61586483..61586487, +
1.76e-45	FFCP PHASE1:Hg19::chr17:39675950..39675974,-	p@chr17:39675950..39675974, -
1.76e-45	FFCP PHASE2:Hg19::chr17:39675950..39675974,-	p@chr17:39675950..39675974, -
4.38e-44	FFCP PHASE1:Hg19::chr3:153697368..153697372,+	p@chr3:153697368..153697372, +
4.38e-44	FFCP PHASE2:Hg19::chr3:153697368..153697372,+	p@chr3:153697368..153697372, +
1.27e-43	FFCP PHASE1:Hg19::chr19:51523412..51523427,-	p2@KLK10
1.27e-43	FFCP PHASE2:Hg19::chr19:51523412..51523427,-	p2@KLK10
4.85e-43	FFCP PHASE1:Hg19::chr17:39675882..39675894,-	p@chr17:39675882..39675894, -
4.85e-43	FFCP PHASE2:Hg19::chrX:15683147..15683159,-	p3@TMEM27
4.85e-43	FFCP PHASE2:Hg19::chr17:39675882..39675894,-	p@chr17:39675882..39675894, -
4.85e-43	FFCP PHASE1:Hg19::chrX:15683147..15683159,-	p3@TMEM27
4.85e-43	FFCP PHASE1:Hg19::chr7:55053219..55053226,+	p@chr7:55053219..55053226, +
4.85e-43	FFCP PHASE2:Hg19::chr7:55053219..55053226,+	p@chr7:55053219..55053226, +
1.42e-40	FFCP PHASE2:Hg19::chr13:74071880..74071894,+	p@chr13:74071880..74071894, +
1.42e-40	FFCP PHASE1:Hg19::chr13:74071880..74071894,+	p@chr13:74071880..74071894, +
1.5e-40	FFCP PHASE1:Hg19::chr5:150998590..150998611,-	p@chr5:150998590..150998611, -
1.5e-40	FFCP PHASE2:Hg19::chr5:150998590..150998611,-	p@chr5:150998590..150998611, -
2.02e-40	FFCP PHASE2:Hg19::chrX:41765898..41765915,-	p@chrX:41765898..41765915, -
2.02e-40	FFCP PHASE1:Hg19::chrX:41765898..41765915,-	p@chrX:41765898..41765915, -
6.43e-40	FFCP PHASE2:Hg19::chr20:30153874..30153891,+	p8@HM13
6.43e-40	FFCP PHASE1:Hg19::chr20:30153874..30153891,+	p8@HM13
2.28e-39	FFCP PHASE1:Hg19::chr17:72940334..72940358,+	p@chr17:72940334..72940358, +
2.28e-39	FFCP PHASE2:Hg19::chr17:72940334..72940358,+	p@chr17:72940334..72940358, +
2.41e-39	FFCP PHASE2:Hg19::chr10:54259403..54259416,+	p@chr10:54259403..54259416, +
2.41e-39	FFCP PHASE1:Hg19::chr10:54259403..54259416,+	p@chr10:54259403..54259416, +
4.5e-38	FFCP PHASE1:Hg19::chr7:55053540..55053550,+	p@chr7:55053540..55053550, +
4.5e-38	FFCP PHASE2:Hg19::chr7:55053540..55053550,+	p@chr7:55053540..55053550, +
2.13e-37	FFCP PHASE2:Hg19::chr11:57558934..57558956,+	p8@CTNND1
2.13e-37	FFCP PHASE1:Hg19::chr11:57558934..57558956,+	p8@CTNND1
1.18e-36	FFCP PHASE2:Hg19::chr12:20975224..20975226,-	p@chr12:20975224..20975226, -
1.18e-36	FFCP PHASE1:Hg19::chr12:20975224..20975226,-	p@chr12:20975224..20975226, -
2.27e-36	FFCP PHASE1:Hg19::chr20:52784969..52785020,+	p@chr20:52784969..52785020, +
2.27e-36	FFCP PHASE2:Hg19::chr20:52784969..52785020,+	p@chr20:52784969..52785020, +
2.56e-36	FFCP PHASE1:Hg19::chr5:39255776..39255791,+	p@chr5:39255776..39255791, +
2.56e-36	FFCP PHASE2:Hg19::chr5:39255776..39255791,+	p@chr5:39255776..39255791, +
2.56e-36	FFCP PHASE1:Hg19::chr17:39678090..39678101,-	p4@KRT15
2.56e-36	FFCP PHASE2:Hg19::chr17:39678090..39678101,-	p4@KRT15
3.32e-36	FFCP PHASE1:Hg19::chr2:31607762..31607771,-	p@chr2:31607762..31607771, -
3.32e-36	FFCP PHASE2:Hg19::chr2:31607762..31607771,-	p@chr2:31607762..31607771, -
1.21e-35	FFCP PHASE2:Hg19::chr9:114557207..114557230,-	p1@C9orf84
1.21e-35	FFCP PHASE1:Hg19::chr9:114557207..114557230,-	p1@C9orf84
1.94e-35	FFCP PHASE2:Hg19::chr9:114490545..114490560,-	p@chr9:114490545..114490560, -
1.94e-35	FFCP PHASE1:Hg19::chr9:114490545..114490560,-	p@chr9:114490545..114490560, -
7.61e-35	FFCP PHASE1:Hg19::chr7:20257377..20257401,+	p@chr7:20257377..20257401, +
7.61e-35	FFCP PHASE2:Hg19::chr7:20257377..20257401,+	p@chr7:20257377..20257401, +
8.78e-35	FFCP PHASE1:Hg19::chr8:128306991..128307011,-	p@chr8:128306991..128307011, -
8.78e-35	FFCP PHASE2:Hg19::chr8:128306991..128307011,-	p@chr8:128306991..128307011, -
1.37e-34	FFCP PHASE1:Hg19::chr20:10400400..10400411,-	p@chr20:10400400..10400411, -
1.37e-34	FFCP PHASE2:Hg19::chr20:10400400..10400411,-	p@chr20:10400400..10400411, -
2.01e-34	FFCP PHASE2:Hg19::chr14:51955719..51955733,+	p15@FRMD6
2.01e-34	FFCP PHASE1:Hg19::chr14:51955719..51955733,+	p15@FRMD6
2.93e-34	FFCP PHASE2:Hg19::chr11:393795..393799,-	p@chr11:393795..393799, -
2.93e-34	FFCP PHASE1:Hg19::chr11:393795..393799,-	p@chr11:393795..393799, -
5.36e-34	FFCP PHASE1:Hg19::chr6:10413321..10413336,+	p@chr6:10413321..10413336, +
5.36e-34	FFCP PHASE2:Hg19::chr6:10413321..10413336,+	p@chr6:10413321..10413336, +
5.82e-34	FFCP PHASE1:Hg19::chr1:115212619..115212636,-	p2@DENND2C
5.82e-34	FFCP PHASE2:Hg19::chr1:115212619..115212636,-	p2@DENND2C
6.3e-34	FFCP PHASE2:Hg19::chr10:105796014..105796053,-	p@chr10:105796014..105796053, -
6.3e-34	FFCP PHASE1:Hg19::chr10:105796014..105796053,-	p@chr10:105796014..105796053, -
8.11e-34	FFCP PHASE1:Hg19::chr11:57558973..57558988,+	p11@CTNND1
8.11e-34	FFCP PHASE2:Hg19::chr11:57558973..57558988,+	p11@CTNND1
1.5e-33	FFCP PHASE1:Hg19::chr6:43423785..43423800,-	p3@DLK2
1.5e-33	FFCP PHASE2:Hg19::chr6:43423785..43423800,-	p3@DLK2
7.55e-33	FFCP PHASE2:Hg19::chr15:79296820..79296829,-	p@chr15:79296820..79296829, -
7.55e-33	FFCP PHASE1:Hg19::chr15:79296820..79296829,-	p@chr15:79296820..79296829, -
1.14e-32	FFCP PHASE2:Hg19::chr12:47628434..47628438,+	p1@CU678929
1.14e-32	FFCP PHASE1:Hg19::chr12:47628434..47628438,+	p1@CU678929
1.46e-32	FFCP PHASE2:Hg19::chr20:10750941..10750951,+	p@chr20:10750941..10750951, +
1.46e-32	FFCP PHASE2:Hg19::chr12:52525577..52525579,-	p@chr12:52525577..52525579, -
1.46e-32	FFCP PHASE1:Hg19::chr12:52525577..52525579,-	p@chr12:52525577..52525579, -
1.46e-32	FFCP PHASE1:Hg19::chr20:10750941..10750951,+	p@chr20:10750941..10750951, +
1.46e-32	FFCP PHASE2:Hg19::chr17:76628163..76628174,-	p@chr17:76628163..76628174, -
1.46e-32	FFCP PHASE1:Hg19::chr17:76628163..76628174,-	p@chr17:76628163..76628174, -

Showing 1 to 100 of 100 entries

@@ Line 13: / Line 13: @@
 |located_in=
 |name=squamous cell carcinoma
-|namespace=disease_ontology
+|namespace=FANTOM
 |obo_creation_date=
 |part_of=

Personal tools

DOID:1749: Difference between revisions - resource_browser

Search

Human

Mouse

Rat

Dog

Chicken

Macaque

Cross species

Other

Tools

DOID:1749: Difference between revisions

From FANTOM5_SSTAR

Latest revision as of 16:49, 12 September 2014

Ontology Tree: Loaded from BioPortal

FF samples

	FAQ
	Mozilla Cavendish skin modified by DaSch for the Web Community Wiki GitHub project page – Report a bug – Skin version: 2.6.0